Associated Papers
Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report.
Zhang Y et al.
Human Vaccines & Immunotherapeutics, 2024
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
Jung S et al.
British Journal of Cancer, 2022
KIT and Melanoma: Biological Insights and Clinical Implications.
Pham DDM et al.
Yonsei Medical Journal, 2020
Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).
Lee SJ et al.
The Oncologist, 2015
V559A and N822I double KIT mutant melanoma with predictable response to imatinib?
McDonnell K et al.
Pigment Cell & Melanoma Research, 2011
Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I.
Orlova KV et al.
Case Reports in Oncology, 0
31043947 (PubMed )
Supplement: cro-0012-0109-s01.pdf
Select a paper to view details